Ionis Pharmaceuticals Inc

16 de set. de 2026, 20:08 UTC

Ionis Pharmaceuticals shares fell amid challenges from its failed Phase 3 ATTR partnership, erasing about $4.63 billion in market value.

15 de set. de 2026, 23:01 UTC

Ionis Pharmaceuticals shares are trading higher in after-market hours, despite a broader market decline indicated by a sharp drop in the Empire State Manufacturing Index.

14 de set. de 2026, 23:16 UTC

Ionis Pharmaceuticals Inc. shares are higher in after-market trading, though still below the 20-day moving average after six consecutive sessions of declines.

11 de set. de 2026, 23:56 UTC

Ionis Pharmaceuticals received FDA approval for ZANVASTRO. Shares are higher in after-market trading, reflecting positive sentiment despite a setback in a partnered trial.

10 de set. de 2026, 19:16 UTC

Ionis Pharmaceuticals shares are lower as HC Wainwright cuts the price target from $115.00 to $100.00 while maintaining a "buy" rating.

9 de set. de 2026, 22:51 UTC

Ionis Pharmaceuticals shares are lower in after-market hours. Broader market trends reflect concerns over rising crude oil prices exceeding $100 amid Middle East tensions.

8 de set. de 2026, 23:41 UTC

Ionis Pharmaceuticals Inc shares are lower in after-market trading, reversing earlier gains and reflecting overall weakness without any specific news to explain the decline.

5 de set. de 2026, 00:05 UTC

Ionis Pharmaceuticals shares are lower in after-market hours following Novartis' announcement that the pelacarsen Phase 3 study did not meet its primary endpoint.

4 de set. de 2026, 23:02 UTC

Ionis Pharmaceuticals shares declined in after-market trading following Novartis' announcement of the failed pelacarsen Phase 3 study to reduce cardiovascular events.

3 de set. de 2026, 22:02 UTC

Ionis Pharmaceuticals shares are higher in after-hours trading following FDA approval for Zanvastro, the first treatment for Alexander disease.

2 de set. de 2026, 23:01 UTC

Ionis Pharmaceuticals Inc shares are lower in after-market hours, reflecting notable selling pressure since Wednesday's close. No specific news was identified to explain the decline.

1 de set. de 2026, 22:01 UTC

Ionis Pharmaceuticals Inc shares are trading higher in after-market hours, reversing a trend of five consecutive lower sessions. No specific news was identified.

31 de ago. de 2026, 19:56 UTC

Ionis Pharmaceuticals shares are lower today following negative results from a failed trial of Wainua, which did not meet its primary endpoint.

28 de ago. de 2026, 21:01 UTC

Ionis Pharmaceuticals Inc. shares are lower in after-market trading, continuing a trend of four consecutive daily declines despite remaining above the 20-day moving average.

27 de ago. de 2026, 23:46 UTC

Ionis Pharmaceuticals shares traded near unchanged during after-market hours, reflecting routine activity. The stock has declined for three consecutive sessions.

26 de ago. de 2026, 23:51 UTC

Ionis Pharmaceuticals is rising in after-market hours, reflecting broader market gains amid positive economic data on durable goods orders and inflation indicators.

25 de ago. de 2026, 23:01 UTC

Ionis Pharmaceuticals Inc shares are higher in after-market hours, maintaining momentum above the 20-day moving average amid a broader market reaction to falling crude oil prices.

24 de ago. de 2026, 23:11 UTC

Ionis Pharmaceuticals shares are higher in after-market hours following a session low. Broader market performance remains subdued amid ongoing geopolitical concerns.

22 de ago. de 2026, 00:01 UTC

Ionis Pharmaceuticals Inc is higher in after-market trading, reflecting strength amid a broader market rebound. The stock remains above its 20-day moving average.

21 de ago. de 2026, 22:51 UTC

Ionis Pharmaceuticals Inc shares are trading higher during after-market hours, remaining above the 20-day moving average and near the upper end of their one-month range.

20 de ago. de 2026, 20:02 UTC

Ionis Pharmaceuticals will present new data on hypertriglyceridemia treatments at the European Society of Cardiology Congress, though shares are trading lower today.

19 de ago. de 2026, 23:06 UTC

Ionis Pharmaceuticals is advancing RG-6299 into a pivotal Phase III trial for IgA nephropathy in collaboration with Roche and Chugai. Shares are higher in after-market trading.

18 de ago. de 2026, 20:06 UTC

Ionis Pharmaceuticals Inc shares are higher, supported by strong momentum above the 20-day moving average. No specific news was identified for today's move.

17 de ago. de 2026, 23:01 UTC

Ionis Pharmaceuticals Inc shares are lower in after-market hours, reflecting a decline since Monday's close amid broader market weakness and geopolitical tensions.

14 de ago. de 2026, 22:02 UTC

Ionis Pharmaceuticals shares are higher in after-market trading. No specific news was identified to explain the movement amid broader economic concerns.

13 de ago. de 2026, 19:56 UTC

Ionis Pharmaceuticals Inc shares are lower today, reflecting broader market trends. First-time unemployment claims rose, but overall investor sentiment remains stable.

12 de ago. de 2026, 23:56 UTC

Ionis Pharmaceuticals Inc. shares are lower in after-market trading, despite remaining above their 20-day moving average and within the upper range for the month.

11 de ago. de 2026, 23:46 UTC

Ionis Pharmaceuticals shares are higher in after-market trading, reaching a high near the upper end of their one-month range. No specific news was identified.

10 de ago. de 2026, 21:01 UTC

Ionis Pharmaceuticals Inc shares are lower in after-market hours. Broader market sentiment is cautious following weaker-than-expected labor market data.

7 de ago. de 2026, 20:03 UTC

Ionis Pharmaceuticals shares are higher today amid increased market volume. HC Wainwright revised Q3 2026 loss estimates, maintaining a "Buy" rating.